Evidence map›Paper›PMID 36348471›Full record

ArticleGenome biology2022

Lineage abundance estimation for SARS-CoV-2 in wastewater using transcriptome quantification techniques.

Jasmijn A Baaijens, Alessandro Zulli, Isabel M Ott, Ioanna Nika, Mart J van der Lugt, Mary E Petrone, Tara Alpert, Joseph R Fauver, Chaney C Kalinich, Chantal B F Vogels and 18 more

Abstract read
In one paragraph

Article in Genome biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Real-time, multi-pathogen wastewater genomic surveillance with Freyja 2.medRxiv : the preprint server for health sciences · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Jasmijn A Baaijens *Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. j.a.baaijens@tudelft.nl.ORCID 0000-0001-5661-0658
Alessandro Zulli *Department of Chemical and Environmental Engineering, Yale University, New Haven, CT, USA.
Isabel M Ott *Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Ioanna NikaDepartment of Intelligent Systems, Delft University of Technology, Delft, Netherlands.
Mart J van der LugtDepartment of Intelligent Systems, Delft University of Technology, Delft, Netherlands.
Mary E PetroneDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Tara AlpertDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Joseph R FauverDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Chaney C KalinichDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Chantal B F VogelsDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Mallery I BrebanDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Claire DuvalletBiobot Analytics, Inc., Cambridge, MA, USA.
Kyle A McElroyBiobot Analytics, Inc., Cambridge, MA, USA.
Newsha GhaeliBiobot Analytics, Inc., Cambridge, MA, USA.
Maxim ImakaevBiobot Analytics, Inc., Cambridge, MA, USA.
Malaika F Mckenzie-BennettGinkgo Bioworks, Inc., Boston, MA, USA.
Keith RobisonGinkgo Bioworks, Inc., Boston, MA, USA.
Alex PlocikGinkgo Bioworks, Inc., Boston, MA, USA.
Rebecca SchillingGinkgo Bioworks, Inc., Boston, MA, USA.
Martha PiersonGinkgo Bioworks, Inc., Boston, MA, USA.
Rebecca LittlefieldGinkgo Bioworks, Inc., Boston, MA, USA.
Michelle L SpencerGinkgo Bioworks, Inc., Boston, MA, USA.
Birgitte B SimenGinkgo Bioworks, Inc., Boston, MA, USA.
Yale SARS-CoV-2 Genomic Surveillance Initiative
William P HanageCenter for Communicable Disease Dynamics and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Nathan D Grubaugh *Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Jordan Peccia *Department of Chemical and Environmental Engineering, Yale University, New Haven, CT, USA.
Michael Baym *Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI HANAGE, WILLIAM · 2009 to 2018
$26.4M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
Short-Term Reserch Training: Students in Health SchoolsT35HL007649 · NHLBI · YALE UNIVERSITY · PI Sarwat I Chaudhry, Erica L Herzog · 1987 to 2026
$5.7M
Evolutionary Tradeoffs in Antibiotic ResistanceR35GM133700 · NIGMS · HARVARD MEDICAL SCHOOL · PI BAYM, MICHAEL · 2019 to 2023
$2.4M
NCATS NIH HHS TL1 TR001864NCATS NIH HHS UL1 TR001863NHLBI NIH HHS T35 HL007649NIGMS NIH HHS R35 GM133700NIGMS NIH HHS U54 GM088558
6 · The paper itself

Abstract

Effectively monitoring the spread of SARS-CoV-2 mutants is essential to efforts to counter the ongoing pandemic. Predicting lineage abundance from wastewater, however, is technically challenging. We show that by sequencing SARS-CoV-2 RNA in wastewater and applying algorithms initially used for transcriptome quantification, we can estimate lineage abundance in wastewater samples. We find high variability in signal among individual samples, but the overall trends match those observed from sequencing clinical samples. Thus, while clinical sequencing remains a more sensitive technique for population surveillance, wastewater sequencing can be used to monitor trends in mutant prevalence in situations where clinical sequencing is unavailable.

Indexed as

COVID-19SARS-CoV-2HumansRNA, ViralTranscriptomeWastewaterRNA, ViralWastewater

Identifiers

PMID36348471
PMCPMC9643916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.